BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250211
DTEND;VALUE=DATE:20250213
DTSTAMP:20260515T112742
CREATED:20250116T115239Z
LAST-MODIFIED:20250117T133524Z
UID:40306-1739232000-1739404799@www.pharmajournalist.com
SUMMARY:3rd Kinase Targeted Drug Discovery Summit
DESCRIPTION:The kinase drug discovery field is at a pivotal moment\, with recent breakthroughs from industry leaders such as Biogen\, A-Alpha Bio\, and Proxygen paving the way for exciting new approaches in targeting kinases\, particularly in targeted protein degradation. \nWith ongoing challenges including selectivity and resistance in small molecule inhibitors\, these hurdles limit the therapeutic applications and call for in-depth discussions focused on innovative future strategies for kinase targeted drugs. \nJoin 60+ peers at the 3rd Kinase Targeted Drug Discovery Summit; the premier\, target-specific conference designed to provide you with ground-breaking insights to revolutionize your kinase biology. \n\nDiscover cutting-edge developments in small molecule therapeutics\, including PROTACs\, molecular glues\, and allosteric inhibitors\nEnhance drug selectivity & tackle resistance head-on\, and identify optimal combination partners\nLead the charge in creating first-class kinase-targeted drugs that can ultimately combat disease indications and transform patient outcomes!\n\nAttendance is complimentary for drug developers & researchers (subject to T&Cs) – we’d love to welcome you to Boston in February!
URL:http://www.pharmajournalist.com/event/3rd-kinase-targeted-drug-discovery-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250218
DTEND;VALUE=DATE:20250220
DTSTAMP:20260515T112742
CREATED:20241127T124753Z
LAST-MODIFIED:20241127T124753Z
UID:40158-1739836800-1740009599@www.pharmajournalist.com
SUMMARY:Neuroscience Innovation Pharma Partnering Summit
DESCRIPTION:Significant breakthroughs in CNS biology\, coupled with innovative neuroscience technologies and a more supportive regulatory landscape\, have fueled increased investment and pharmaceutical interest in the CNS. \nWith AbbVie\, BMS\, and Lundbeck making major acquisitions in the last 12 months alone\, this wave of deal-making is redemption for biotech who kept the lights on and are building with greater strength than before. \nJoin the Neuroscience Innovation Pharma Partnering Summit to: \n\nConnect with a targeted critical mass of decision-makers aligned with your strategic and scientific goals.\nBuild stronger relationships with key pharma and investor contacts to emphasize your company’s competitive edge\nPosition your company at the front of scientific innovation to show where you add value\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/neuroscience-innovation-pharma-partnering-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250219
DTEND;VALUE=DATE:20250222
DTSTAMP:20260515T112742
CREATED:20241122T121650Z
LAST-MODIFIED:20241122T121650Z
UID:40111-1739923200-1740182399@www.pharmajournalist.com
SUMMARY:3rd Viral Vector Process Development & Manufacturing Summit
DESCRIPTION:In recent industry news\, AAV gene therapies are gaining momentum\, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome\, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy market\, valued at $1.5 billion in 2023\, is projected to skyrocket to $22.3 billion by 2029. However\, scaling up production remains a significant challenge\, highlighting the urgency for innovative solutions in viral vector manufacturing.​ \nThe 3rd Viral Vector Process Development & Manufacturing Summit returns to Boston to tackle these challenges head-on. Featuring over 16 expert speakers\, including Yuanli Song\, Associate Director at Sanofi\, the event offers cutting-edge insights into process optimization for viral vector production. Yuanli Song emphasized the importance of this summit\, saying\, “This summit is a vital platform that brings together experts from diverse fields to address and solve pressing challenges in viral vector process development and manufacturing. The 2025 meeting will witness valuable discussions that will help drive innovation and advance solutions for optimizing viral vector production.” \nThe agenda includes two interactive workshops and over 20 hours of insightful content designed to address upstream and downstream challenges\, improve yield\, and enhance scalability. Additionally\, attendees will benefit from 6+ hours of dedicated networking breaks\, fostering collaborations crucial for advancing this field. \nKey topics covered include: \n\nEnhancing capsid ratios and vector optimization\nInnovations in purification techniques\nSeamless tech transfer for scalability\nTackling high-dose production complexities\n\nThis summit is the ultimate opportunity for professionals from companies like Sanofi\, Kite\, Ultragenyx\, and others to stay at the forefront of viral vector manufacturing innovations. With 800+ gene therapy candidates in trials and the FDA’s evolving frameworks\, this event is essential for driving the next wave of scalable\, high–quality therapies​. \nView our agenda to find out more!
URL:http://www.pharmajournalist.com/event/3rd-viral-vector-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T112742
CREATED:20241024T112821Z
LAST-MODIFIED:20241024T112821Z
UID:39941-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:8th Antigen-Specific Immune Tolerance Drug Development Summit
DESCRIPTION:Advancing Curative Therapies for Autoimmune Diseases  \nBuilding on the success of last year’s meeting\, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. \nAgenda highlights include: \n\nStandardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy\nDelving into antigen selection for complex autoimmune diseases with multiple antigen drivers to expand the wheelhouse of diseases immune tolerizing strategies can target including celiac disease\, Type 1 diabetes\, multiple sclerosis\, rheumatoid arthritis\, IBD\, and more\nAdvancing durable and efficacious ASIT therapeutics through early-stage clinical trials and beyond\n\nJoin your colleagues and thought leaders in February to take actionable insights back to your team at the industry’s only\, dedicated\, antigen-specific immune tolerance meeting. Join Eli Lilly\, AbbVie\, Pfizer\, Diamyd\, Moderna\, Toleranzia\, GRO Bio and more. \nFind out more here: https://ter.li/ujeia4
URL:http://www.pharmajournalist.com/event/8th-antigen-specific-immune-tolerance-drug-development-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T112742
CREATED:20241029T113934Z
LAST-MODIFIED:20241029T113934Z
UID:39973-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:8th CAR-TCR Summit Europe
DESCRIPTION:Investors in the cell therapy industry are actively looking into solid tumours\, autoimmune indications and novel engineering as the best place to allocate their money and resources. This\, along with the recent investments in Enara Bio\, ArsenalBio\, Kyverna and Artiva signifies that the field is poised to regain momentum. \nIt’s not just investments that are gaining traction. Recent approvals are changing the game\, with Iovance and Adaptimmune making strides in treating solid tumours\, Kite securing first-line treatment approval\, and donor cell therapies\, demonstrating success in putting autoimmune diseases into remission. The industry is brimming with new hope! \nThe 8th CAR-TCR Summit Europe returns to London this February as your must-attend forum to remain on the pulse of recent innovation in cell therapy. Join us to collaborate\, innovate\, and overcome the shared challenges of safety concerns\, high cost of goods\, effective tumour targeting\, and more. Let’s work together to drive success in clinical trials\, secure regulatory approvals\, and position cell therapy as the first-line treatment for oncological and non-oncological indications. \nView the agenda here: https://ter.li/6qjg6t \nSnapshot of the 50+ expert speaker faculty: \n\nBirk Vanderween\, Senior Vice President\, Global Manufacturing & Supply\, Legend Biotech \nCokey Nguyen\, President & Chief Executive Officer\, Atara Biotherapeutics \nDanielle Quarles\, Executive Director\, Clinical Operations\, Sana Biotechnology\nFranco Locatelli\, Professor\, Catholic University of Sacred Heart\, Bambion Gesu Children’s Hospital \nGwendolyn Binder\, President\, Science & Technology\, Cabaletta Bio \nMarlene Carrasco Alfonso\, Global Head Immunology Cell Therapy\, AstraZeneca \nNancy Boman\, Chief Regulatory Officer\, Adicet Bio \nRaha Jahromi\, Associate Director\, Kite\, A Gilead Company\n\nLearn more: https://ter.li/6qjg6t
URL:http://www.pharmajournalist.com/event/8th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T112742
CREATED:20241031T112011Z
LAST-MODIFIED:20241031T112011Z
UID:39992-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:4th mRNA Analytical Development & Quality Control Summit
DESCRIPTION:4th mRNA Analytical Development & Quality Control Summit | February 25-27\, 2025 \nExcitement for mRNA therapeutics continues\, as RNA technologies are awarded the Nobel Prize for the second year running. Yet\, despite optimized analytics\, critical quality control methodology and robust assay development leading to efficient approvals and commercialization\, knowledge gaps persist in phase-appropriate assays\, analyzing LNP payloads and novel cell-targeted delivery systems\, and controlling dsRNA. Not to mention the challenges posed by regulations! \nWith exclusive FDA insight\, the 4th mRNA Analytical Development & Quality Control Summit returns; uniting the Analytical\, Quality\, and Assay Development teams at one central forum for the first time to finally address shared challenges and cross-department priorities to ensure successful regulatory submissions. \n\nDates: February 25-27\, 2025\nLocation: Revere Hotel Boston Common\, Boston\, Massachusetts\nEvent Program: https://ter.li/h10rnn\n\nBringing together 100+ Scientists\, Directors and Heads of Analytical Development\, Quality Control\, Assay Development\, CMC and Regulatory Affairs\, join your peers to take part in critical conversations and ensure the identity\, safety and efficacy of your RNA medicines. \nDownload the agenda here: https://ter.li/h10rnn \nView your registration options\, early bird savings\, and group discounts: https://ter.li/ku4oky \n 
URL:http://www.pharmajournalist.com/event/4th-mrna-analytical-development-quality-control-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T112742
CREATED:20241204T185205Z
LAST-MODIFIED:20241204T185205Z
UID:40215-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:TRP Target Selection & Drug Design Summit
DESCRIPTION:The radiopharmaceutical race is on and pharma leaders such as AstraZenca\, BMS \, Eli Lilly\, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology\, Radionetics and Aktis Oncology\, the field is turning to cutting-edge\, novel targeting molecules and new targets to address more unmet medical need. With strong clinical efficacy from blockbuster drugs Pluvicto and Lutathera\, radiopharmaceutical leaders are looking for the next application of this highly efficacious and potent modality! \nThe inaugural Targeted Radiopharmaceuticals Target Selection & Drug Design Summit is your dedicated forum to advancing novel radiopharmaceutical drug discovery. Delve deep into target mining\, screening\, discovery and selection from ROR1\, uPAR\, B7-H3\, NECTIN-4\, CAIX and more. Understand advances in radiobiological\, radiodecay and radiation absorption mechanisms to inform optimal targeting strategies from small molecule\, peptide\, nanobodies\, antibody fragments as well as linker and chelator technologies for enhanced PK. Bringing it all together\, gain a commercial perspective to enhance your strategic decision-making in target selection and novel drug rationale within this highly dynamic field. \nIncorporating key insights from radiopharmaceuticals’ leading drug discovery minds from medicinal chemistry\, radiobiology\, biology\, discovery\, R&D\, pharmacology\, computational biology\, commercial strategy and many more\, this is the only global opportunity to gain practical insights into your approaches\, from target selection to drug design. \nUniting the discovery experts pioneering the field\, join the inaugural TRP Target Selection & Drug Design Summit to understand exactly what targets match the strong therapeutic index of TRPs and uncover optimal targeting strategies for stellar drug discovery! \nTo know more visit: https://ter.li/95a3xm
URL:http://www.pharmajournalist.com/event/trp-target-selection-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR